CareDx, Inc. (CDNA): Price and Financial Metrics
CDNA Stock Summary
- CDNA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,044.13 -- higher than 95.83% of US-listed equities with positive expected earnings growth.
- The price/operating cash flow metric for CareDx Inc is higher than 95.63% of stocks in our set with a positive cash flow.
- Revenue growth over the past 12 months for CareDx Inc comes in at 51.25%, a number that bests 90.34% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to CareDx Inc are BGMD, CLXT, GKOS, LC, and WK.
- CDNA's SEC filings can be seen here. And to visit CareDx Inc's official web site, go to www.caredx.com.
CDNA Stock Price Chart Interactive Chart >
CDNA Price/Volume Stats
|Current price||$74.27||52-week high||$99.83|
|Prev. close||$77.18||52-week low||$21.75|
|Day high||$77.67||Avg. volume||774,946|
|50-day MA||$74.78||Dividend yield||N/A|
|200-day MA||$57.06||Market Cap||3.85B|
CareDx, Inc. (CDNA) Company Bio
CareDx, Inc. focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is based in Brisbane, California.
CDNA Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
We started the process of determining a valid price forecast for CareDx Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that CareDx Inc ranked in the 84th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 441.67%. As for the metrics that stood out in our discounted cash flow analysis of CareDx Inc, consider:
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 4.76% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than just 0% of stocks in its sector (Healthcare).
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
CDNA Latest News Stream
|Loading, please wait...|
CDNA Latest Social Stream
View Full CDNA Social Stream
Latest CDNA News From Around the Web
Below are the latest news stories about CareDx Inc that investors may wish to consider to help them evaluate CDNA as an investment opportunity.
Company to showcase its latest integrated solutions for improving care across the whole transplant journeySOUTH SAN FRANCISCO, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will be exhibiting at the 29th Annual UNOS Transplant Management Forum (TMF), which takes place virtually between April 19-22, 2021. On April 20, 2021 at 11:00 a.m. EDT, CareDx will be hosting a symposium titled “Providing Personalized Care for Every Step on the Transplant Journey,” which will include the following topics: The Transplant PatientPre-transplant Care with TX Conn...
Initial projects underway for global pharmaceutical companySOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that they have launched a fully-functional next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden to support companies in research and academic studies working on HLA applications in vaccine and drug development as well as disease association studies. The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of...
CareDx Builds for the Future by Investing in TalentSOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of new senior leaders to create meaningful impact across key growth areas, build for the future, and enhance the patient journey. “As we grow, we will continue to bring incredibly talented senior leaders to build the CareDx Village,” said Reg Seeto, President and Chief Executive Officer, CareDx. ”These recent hires and promotions reinforce our commitment to leadership in multi-modality innovation, places priority on p...
SOUTH SAN FRANCISCO, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the…
Alger, an investment management firm, published its ‘Alger Small Cap Focus Fund’ fourth quarter 2020 investor letter – a copy of which can be downloaded here. In the letter, the fund highlighted their largest portfolio sector weightings, which is in the Health Care and Information Technology sector, and their comments on notable companies. You can […]
CDNA Price Returns
Continue Researching CDNAWant to see what other sources are saying about CareDx Inc's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!